Evidence map›Paper›PMID 42564156›Full record

ReviewFrontiers in aging neuroscience2026

Nada Ali, Noelle Chakbazof, Sara Ghasem Pour, Lorena Contreras, Jimena Estrada, Gene E Alexander, David A Raichlen, Hussein N Yassine

Abstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nada AliDepartment of Neurology, University of Southern California, Los Angeles, CA, United States.
Noelle ChakbazofDepartment of Neurology, University of Southern California, Los Angeles, CA, United States.
Sara Ghasem PourDepartment of Neurology, University of Southern California, Los Angeles, CA, United States.
Lorena ContrerasDepartment of Neurology, University of Southern California, Los Angeles, CA, United States.
Jimena EstradaDepartment of Neurology, University of Southern California, Los Angeles, CA, United States.
Gene E AlexanderDepartment of Psychology, University of Arizona, Tucson, AZ, United States.
David A RaichlenDepartment of Biological Sciences, University of Southern California, Los Angeles, CA, United States.
Hussein N YassineDepartment of Neurology, University of Southern California, Los Angeles, CA, United States.

Funding

USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
The delivery of essential fatty acids to the Brain in Alzheimer's diseaseR01AG054434 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$5.4M
Biomarkers of ABCA1 mediated functions in Alzheimers diseaseR01AG055770 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$4.2M
ApoE, ABCA1 and endosomal dysregulation in ADR01AG067063 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2020 to 2024
$3.4M
Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4 Diversity SupplementRF1AG076124 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARVANITAKIS, ZOE, YASSINE, HUSSEIN N · 2022 to 2024
$2.5M
DHA brain delivery by APOE genotypeR21AG056518 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2018 to 2019
$464k
NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG054434NIA NIH HHS R01 AG055770NIA NIH HHS R01 AG067063NIA NIH HHS R21 AG056518NIA NIH HHS RF1 AG076124
6 · The paper itself

Abstract

Background: Physical activity (PA) is often proposed as a modifiable strategy to reduce cognitive decline and dementia risk, particularly among individuals at elevated genetic risk for Alzheimer's disease (AD). However, it remains unclear whether the existing literature tests PA at the disease stage and in the populations most likely to show benefit. Objective: This umbrella review evaluated whether associations between PA and cognitive, fluid biomarker, neuroimaging, and vascular/metabolic outcomes differ by apolipoprotein E ε4 ( Methods: Systematic reviews and meta-analyses were screened for primary studies examining PA in adults classified by baseline cognitive status as cognitively unimpaired, mild cognitive impairment (MCI), or dementia. Primary studies reporting Results: Of 2,100 records identified, seven systematic reviews met inclusion criteria, yielding 68 unique primary studies. Favorable associations between PA and cognitive, biomarker, neuroimaging, and vascular/metabolic outcomes were most often reported in observational studies of younger or cognitively unimpaired adults. Several studies suggested stronger associations among Conclusion: The current evidence does not establish a definitive

Indexed as

Alzheimer’s diseaseAPOE4 alleleexercisephysical activityvascular

Identifiers

PMID42564156
PMCPMC13442396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.